Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | WNT3A | P56704 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819179 | 0.82 | ALDH1A1 (0.40) | ALDH1A1HPGDMAPTWNT3ACYP3A4 | |
| SCHEMBL3034763 | 0.77 | ALDH1A1 (0.62) | ALDH1A1HPGDMAPTWNT3AKMT2A | |
| SCHEMBL11899820 | 0.76 | MEN1 (0.41) | ALDH1A1KMT2AMEN1SMN1; SMN2CTSA | |
| SCHEMBL1065313 | 0.75 | ALDH1A1 (0.62) | ALDH1A1HPGDMAPTWNT3AKMT2A | |
| SCHEMBL1064326 | 0.75 | ALDH1A1 (0.62) | ALDH1A1HPGDMAPTWNT3AKMT2A | |
| SCHEMBL1064538 | 0.73 | CACNA1I (0.72) | ALDH1A1HPGDMAPTKMT2AMEN1 | |
| SCHEMBL6901625 | 0.72 | CACNA1H (0.50) | ALDH1A1HPGDMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1062846 | 0.71 | CACNA1I (0.60) | ALDH1A1HPGDMAPTKMT2AMEN1 | |
| SCHEMBL17451447 | 0.71 | ALDH1A1 (0.57) | ALDH1A1HPGDMAPTWNT3AKMT2A | |
| SCHEMBL1064346 | 0.71 | CACNA1I (0.66) | ALDH1A1HPGDMAPTWNT3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | claimed |
| EP-2493297-B1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2493297-B1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-08-17 | — | — | EP | disclosed |
| US-8987310-B2 | Heterocycle amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987310-B2 | Heterocycle amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987310-B2 | Heterocycle amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | disclosed |
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | disclosed |
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-08-09 | — | — | US | disclosed |
| WO-2011053542-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202852-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | ALDH1A1 3841/4885HPGD 617/4885MAPT 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.